Annual Operating Expenses
$198.32 M
+$9.50 M+5.03%
December 31, 2023
Summary
- As of February 7, 2025, ADAP annual total operating expenses is $198.32 million, with the most recent change of +$9.50 million (+5.03%) on December 31, 2023.
- During the last 3 years, ADAP annual operating expenses has risen by +$60.96 million (+44.38%).
- ADAP annual operating expenses is now at all-time high.
Performance
ADAP Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$55.58 M
-$3.95 M-6.64%
September 30, 2024
Summary
- As of February 7, 2025, ADAP quarterly total operating expenses is $55.58 million, with the most recent change of -$3.95 million (-6.64%) on September 30, 2024.
- Over the past year, ADAP quarterly operating expenses has increased by +$642.00 thousand (+1.17%).
- ADAP quarterly operating expenses is now -6.64% below its all-time high of $59.53 million, reached on June 30, 2024.
Performance
ADAP Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
ADAP Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +5.0% | +1.2% |
| 3 y3 years | +44.4% | +28.1% |
| 5 y5 years | +39.8% | +37.7% |
ADAP Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +17.8% | -6.6% | +54.5% |
| 5 y | 5-year | at high | +44.4% | -6.6% | +82.1% |
| alltime | all time | at high | +2020.9% | -6.6% | +906.0% |
Adaptimmune Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $55.58 M(-6.6%) |
| Jun 2024 | - | $59.53 M(+8.4%) |
| Mar 2024 | - | $54.94 M(+9.7%) |
| Dec 2023 | $198.32 M(+5.0%) | $50.09 M(-7.2%) |
| Sep 2023 | - | $53.95 M(+7.8%) |
| Jun 2023 | - | $50.04 M(+13.1%) |
| Mar 2023 | - | $44.24 M(+23.0%) |
| Dec 2022 | $188.82 M(+12.1%) | $35.97 M(-28.0%) |
| Sep 2022 | - | $50.00 M(+1.4%) |
| Jun 2022 | - | $49.29 M(-8.0%) |
| Mar 2022 | - | $53.56 M(+20.9%) |
| Dec 2021 | $168.40 M(+22.6%) | $44.28 M(+2.1%) |
| Sep 2021 | - | $43.38 M(+2.3%) |
| Jun 2021 | - | $42.41 M(+10.7%) |
| Mar 2021 | - | $38.32 M(-1.8%) |
| Dec 2020 | $137.36 M(-2.5%) | $39.02 M(+5.3%) |
| Sep 2020 | - | $37.07 M(+20.5%) |
| Jun 2020 | - | $30.75 M(+0.8%) |
| Mar 2020 | - | $30.52 M(-1.8%) |
| Dec 2019 | $140.89 M | $31.08 M(-23.0%) |
| Sep 2019 | - | $40.36 M(+13.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2019 | - | $35.66 M(+5.5%) |
| Mar 2019 | - | $33.79 M(+0.6%) |
| Dec 2018 | $141.87 M(+19.7%) | $33.59 M(-0.6%) |
| Sep 2018 | - | $33.77 M(-10.9%) |
| Jun 2018 | - | $37.91 M(+2.7%) |
| Mar 2018 | - | $36.94 M(+8.7%) |
| Dec 2017 | $118.49 M(+36.2%) | $33.97 M(+5.7%) |
| Sep 2017 | - | $32.15 M(+17.7%) |
| Jun 2017 | - | $27.30 M(+8.9%) |
| Mar 2017 | - | $25.08 M(+8.1%) |
| Dec 2016 | $87.00 M(+145.8%) | $23.19 M(+10.3%) |
| Sep 2016 | - | $21.03 M(-8.7%) |
| Jun 2016 | - | $23.03 M(+16.6%) |
| Mar 2016 | - | $19.74 M(+38.7%) |
| Dec 2015 | $35.39 M(+2.5%) | - |
| Sep 2015 | - | $14.24 M(+125.9%) |
| Jun 2015 | $34.51 M(+179.5%) | - |
| Dec 2014 | - | $6.30 M(+14.0%) |
| Sep 2014 | - | $5.53 M |
| Jun 2014 | $12.35 M(+32.0%) | - |
| Jun 2013 | $9.35 M | - |
FAQ
- What is Adaptimmune Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual operating expenses year-on-year change?
- What is Adaptimmune Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly operating expenses year-on-year change?
What is Adaptimmune Therapeutics annual total operating expenses?
The current annual operating expenses of ADAP is $198.32 M
What is the all time high annual operating expenses for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual total operating expenses is $198.32 M
What is Adaptimmune Therapeutics annual operating expenses year-on-year change?
Over the past year, ADAP annual total operating expenses has changed by +$9.50 M (+5.03%)
What is Adaptimmune Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of ADAP is $55.58 M
What is the all time high quarterly operating expenses for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly total operating expenses is $59.53 M
What is Adaptimmune Therapeutics quarterly operating expenses year-on-year change?
Over the past year, ADAP quarterly total operating expenses has changed by +$642.00 K (+1.17%)